News

Mankind Pharma Limited announced the allotment of 49,112 equity shares to eligible employees under its Mankind Employee Stock Option Plan 2022, according to a regulatory filing on September 1, 2026. The shares, with a face value of Rs 1 each, were issued at an exercise price of Rs 860 per share and a premium of Rs 859 per share, increasing the company`s paid-up share capital from 41,29,95,978 equity shares to 41,30,45,090 equity shares.

Mankind Pharma Limited announced that its board approved the voluntary liquidation of its 96% owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), with Appian Properties Private Limited, a wholly owned subsidiary of Mankind Pharma, holding the remaining 4% stake. The business of BSVL will be consolidated with Mankind Pharma on a going concern basis, with Appian receiving cash proportionate to its shareholding based on an independent valuation.

Mankind Pharma Limited announced that its board approved the voluntary liquidation of its wholly owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), in which Mankind Pharma holds 96% stake, with the remaining 4% held by Appian Properties Private Limited, also a Mankind Pharma subsidiary. The business of BSVL will be consolidated with Mankind Pharma on a going concern basis, and Appian will receive cash proportionate to its 4% shareholding, as determined by an independent valuer.

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 30 July 2026.

The board of Mankind Pharma at its meeting held on 11 July 2026, has inter-alia, considered and approved the: proposal for divestment of 100% stake held in Broadway Hospitality Services (Broadway), a wholly owned subsidiary company; and incorporation of a wholly owned subsidiary company in Netherlands (WOS) to act as a Special Purpose Vehicle for holding investments in R&D assets and business development activities focused on treatment of niche therapies.